An 18-Year Experience Utilizing Distal Revascularization With Interval Ligation (DRIL) as the Primary Treatment for Hand Ischemia Following Dialysis Access Creation  by Aimaq, Rahim & Katz, Steven
T
C
T
p
b
c
u
n
s
c
m
c
w
(
3
a
e
d
p
T
A
C
C
V
I
o
B
J
V
L
(
d
(
m
M
w
1
i
w
4
w
5
a
n
(
c
a
t
l
d
p
9
m
a
c
i
JOURNAL OF VASCULAR SURGERY
August 2012580 AbstractsAn 18-Year Experience Utilizing Distal Revascularization With Inter-
val Ligation (DRIL) as the Primary Treatment for Hand Ischemia
Following Dialysis Access Creation
Rahim Aimaq, MD, and Steven Katz, MD. Vascular Surgery, Huntington
Memorial Hospital, Pasadena, Calif
Objective: Arterial steal syndrome after angioaccess surgery can lead to
potentially devastating complications. Past treatments ensured loss of the
newly created access by performing ligation or attempted salvage by increas-
ing resistance within the fistula. None of these proved to be entirely
satisfactory. In 1994, we began to use distal revascularization with interval
ligation (DRIL) as our primary method of relieving hand ischemia after
dialysis access creation. We describe our experience with this procedure.
Methods: After Investigational Review Board approval, the records of
all patients undergoing the DRIL procedure for relief of hand ischemia after
dialysis access surgery were reviewed. Patient demographics, risk factors,
type of fistula, and indications for operation were recorded. The clinical
results of DRIL surgery, duration of fistula use for dialysis, and bypass graft
patency were noted. Kaplan-Meier survival curves were created, and differ-
ences between groups were tested by the log-rank method. Fistula survival
was defined as the duration of use before abandonment as the primary
method of achieving dialysis access, and bypass graft survival was determined
by clinical examination or duplex scan.
Results: Between May 1994 and August 2011, 81 DRIL procedures
were performed on 77 patients (32 men, 45 women) with a mean age of 64
years (range, 37-91 years). Diabetes was present in 77.6%. DRIL procedures
were performed for ischemic symptoms after 51 autogenous fistulas (37 bra-
chiocephalic and 14 brachiobasilic), and 30 were created after prosthetic bridge
fistulas. Thirty-eight DRILS were performed for patients with ischemic rest
pain, 20 after the development of digital ulcers, 16 to help resolve neurologic
symptoms, and seven to heal digital gangrene. After performance of the DRIL
procedure, complete resolution of symptoms was noted in 90% of patients
treated for digital ulceration, 81.6% of patients treated for ischemic rest pain,
56.3% of patients treated for neurologic deficits, and 42.9% of patients treated
for digital gangrene. Overall fistula survival after the DRIL procedure was
70.1%, 57.8%, and 44.5% at 12, 24, and 36 months, respectively. Autogenous
fistulas had a significantly longer survival after DRIL than prosthetic bridge
fistulas (P .009). The 5-year patency of the brachial-brachial bypass graft was
93.7%. No patients died30 days of operation.
Conclusions: The DRIL procedure is a very effective treatment of hand
ischemia after dialysis access creation and can be performed with a low mortality.
It is extremely successful in treating ischemic rest pain and digital ulceration, but
less so when used to treat patients with digital gangrene and neurologic deficits.
Autogenous fistula survival after the creation of the DRIL is excellent and
considerably longer than that of prosthetic bridge fistulas.
Placement of a Brachial-Hemiazygous Arteriovenous Graft for Hemo-
dialysis Using the Gore Hybrid Graft
Swee Lian Tan, MD, PhD, and Robert B. Osnis, MD. Department of
Vascular Surgery, Swedish Medical Center, Seattle, Wash
Objective: To develop additional options for hemodialysis access after
common sites for arteriovenous (AV) fistulae and grafts have been ex-
hausted, but before resorting to higher-risk sites, such as the vena cava and
right atrium, we report the use of a new hybrid stent graft to access and
secure an AV graft to a traditionally difficult-to-expose and fragile vein.
Methods: We identified a patient with end-stage renal disease with a
failing cross-pubic femoral artery-to-external iliac vein graft with a history of
multiple failed AV grafts and central venous occlusions. The patient was no
longer a candidate for peritoneal dialysis or renal transplant. A 9-mm Gore
Hybrid graft was introduced into the hemiazygous vein percutaneously
through a site at the base of the neck. After the stent portion of the graft was
deployed in the vein, the graft was placed in a subcutaneous tunnel from the
neck to the left brachial artery, where a conventional anastomosis was
performed. In another patient, the same technique was used to implant an
AV graft between the subclavian vein and the brachial artery.
Results: The graft was successfully placed without complication, and
dialysis pump speeds of 400 mL/min were achieved.
Conclusions: The Gore Hybrid graft has been primarily used to
simplify and speed placement of AV grafts using conventional vessels.
However, in patients where those vessels are no longer available, it can also
be used on vasculature that has been considered too difficult or risky to use
as a graft site using traditional surgical techniques.
Routine Genetic Testing Should be Standard of Care for Patients
Receiving Oral Anticoagulants
Karthik Kasirajan, MD,1 and Stephen Murray, MD2. 1NMTC, Walnut
Creek, Calif; and 2Providence Hospital, Spokane, Wash
Objective: A significant number of patients who receive anticoagulants
experience major or minor bleeding events or continue to experience
thrombotic complications. Black box warnings on the labels of the two most
commonly prescribed oral anticoagulants (clopidogrel and warfarin) inform
physicians that genetic differences can reduce or augment drug effectiveness.
f
they additionally include information on the available genetic tests:
YP2C19 status for clopidogrel andCYP2C9/VKORC1 status for warfarin.
his study assessed the incidence of gene variations that may influence
atient response to both drugs.
Methods: Molecular laboratory analysis was performed from four
uccal swabs done on each patient. CYP2C19 (n 6664) test subjects were
lassified as normal, normal intermediate, intermediate, poor, rapid, or
ltrarapid metabolizers. CYP2C9 (n 6073) test subjects were classified as
ormal, intermediate, or poor metabolizers. VKORC1 (n  6066) test
ubjects were classified as low, intermediate, or high sensitivity.
Results: Overall genetic variations that would affect clopidogrel effi-
acy were more common (n  4054 [60.8%]) compared with normal
etabolizers (n  2610 [39%]). Poor and ultrarapid metabolizers ac-
ounted for 3% and 4%, respectively. Genetic variations that would affect
arfarin metabolism in the CYP2CP assay were noted in 1700 patients
28%). VKORCI assay was nonintermediate (low and high sensitivity) in
424 patients (56.5%).
Conclusions: A significant percentage of the patients taking oral antico-
gulants, especially clopidogrel, have genetic variations that determine drug
fficacy. On the basis of our study, we would recommend that patients receiving
rugs with a narrow therapeutic margin should have a mandatory molecular
rofiling to best determine a safe, effective and individualized drug dosage.
able. Phenotype of genetic assay
ssay response No. (%)
YP2C19
Normal 2610 (39.2)
Poor/intermediate 1954 (29.3)
Rapid/ultrarapid 2100 (31.5)
YP2CP
Normal 4373 (72)
Intermediate 1552 (25.6)
Poor 148 (2.4)
KORC1
Low 2672 (44)
Intermediate 2642 (43.6)
High 752 (12.4)
mportance of Intravascular Ultrasound Imaging During Percutane-
us Treatment of May-Thurner Syndrome
rian G. DeRubertis, MD, Wesley Lew, MD, Sinan Jabori, Andy Barleban, MD,
uan Carlos Jimenez, MD, and Peter F. Lawrence, MD. Division of
ascular Surgery, University of California-Los Angeles School of Medicine,
os Angeles, Calif
Objective: May-Thurner (MT) compression of the left common iliac
LCIV) vein can present as unilateral leg swelling with or without associated
eep vein thrombosis (DVT). This report describes our diagnostic approach
with emphasis on the importance of intravascular ultrasound imaging),
anagement, and outcome in these patients.
Methods: This was a retrospective analysis of all patients evaluated for
T from 2006 to 2011.
Results: MT was diagnosed in 27 patients (63% female) who presented
ith unilateral left leg swelling, with (n  15, thrombotic) or without (n 
2, nonthrombotic) associated DVT. All patients underwent duplex imag-
ng and contrast angiography, and intravascular ultrasound (IVUS) imaging
as performed in 11 (83% of those with nonthrombotic MT). Mean age was
2.9 years. Prior DVT, pulmonary embolism, and hypercoagulable state
ere each present in 25% of nonthrombotic patients and in 80%, 33%, and
3% of thrombotic patients, respectively. Pain and swelling were present in
ll patients, and venous claudication was present in 63%. At presentation, all
onthrombotic patients were CEAP C3; thrombotic patients were C3
86.7%) or C6 (13.3%). Four of the nonthrombotic patients were treated
onservatively. Eight underwent LCIV stenting, leading to reduction or
melioration of symptoms in 87.5% and a decreased CEAP score in 75%. For
hrombotic patients, all but one underwent LCIV stenting (with or without
ysis), resulting in alleviation or amelioration of symptoms in 100% and
ecreased CEAP score in 85.7%. Angiographic findings in nonthrombotic
atients included LCIV stenosis, collateralization, and contrast stagnation in
1.7%, 83.3%, and 75% respectively. However, contrast angiography overesti-
ated LCIV minimum diameter by 61% (7.0 vs 4.2 mm) and cross-sectional
rea by twofold (104 vs 53 cm2) relative to IVUS imaging. Correction of LCIV
ompression in nonthrombotic patients was associated with a threefold increase
n mean cross-sectional area (53 to 166 cm2). One-year primary patency (mean
ollow-up, 9.7 months) was 100% for nonthrombotic patients and 78.6% for
hrombotic patients, with 100% secondary patency for both. Complications
